Iqvia have announced that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This milestone reflects the growing need for flexibility in clinical research and the proliferation of technology-enabled options that enable decentralized trials. “Patient-centricity is at the core of decentralized and hybrid trial design. We used to bring the patient to the trial, but now we bring the trial to the patient,” said Costa Panagos, president, R&D Operations, IQVIA. “The idea is to design trials that fit into patients’ lives in a way that is seamless with their day-to-day activities and to capture important trial information, while reducing the burden on patients and investigators alike. It also means we adapt the way we support investigative sites globally with our study concierge service and other white glove solutions.” IQVIA’s virtual model offers the adaptability necessary to meet a sponsor’s operational requirements. The solution is supported by a range of IQVIA capabilities including direct-to-patient engagement, telehealth technologies, virtual site management, and home health nursing. Read more